Literature DB >> 18521796

Identifying candidate genes involved in brain tumor formation.

Fredrik Johansson Swartling1.   

Abstract

Malignant primary brain tumors, gliomas, often overexpress both platelet-derived growth factor (PDGF) ligands and receptors providing an autocrine and/or paracrine boost to tumor growth. Glioblastoma multiforme (GBM) is the most frequent glioma. Its aggressive and infiltrative growth renders it extremely difficult to treat. Median survival after diagnosis is currently only 12-14 months. The present review describes the use of retroviral tagging to identify candidate cancer-causing genes that cooperate with PDGF in brain tumor formation. Newborn mice injected intracerebrally with a Moloney murine leukemia retrovirus carrying the sis/PDGF-B oncogene and a replication competent helper virus developed brain tumors with many characteristics of human gliomas. Analysis of proviral integrations in the brain tumors identified almost 70 common insertion sites (CISs). These CISs were named brain tumor loci and harbored known but also putative novel cancer-causing genes. Microarray analysis identified differentially expressed genes in the mouse brain tumors compared to normal brain. Known tumor genes and markers of immature cells were upregulated in the tumors. Tumors developed 13-42 weeks after injection and short latency tumors were further distinguished as fast growing and GBM-like. Long latency tumors resembled slow-growing oligodendrogliomas and contained significantly less integrations as compared to short latency tumors. Several candidate genes tagged in this retroviral screen have known functions in neoplastic transformation and oncogenesis. Some candidates with a previously unknown function in tumorigenesis were found and their putative role in brain tumor formation will be discussed in this review. The results show that proviral tagging may be a useful tool in the search for candidate glioma genes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18521796     DOI: 10.3109/2000-1967-215

Source DB:  PubMed          Journal:  Ups J Med Sci        ISSN: 0300-9734            Impact factor:   2.384


  10 in total

1.  CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.

Authors:  Joseph A Flores-Toro; Defang Luo; Adithya Gopinath; Matthew R Sarkisian; James J Campbell; Israel F Charo; Rajinder Singh; Thomas J Schall; Meenal Datta; Rakesh K Jain; Duane A Mitchell; Jeffrey K Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-26       Impact factor: 11.205

Review 2.  Insights into molecular therapy of glioma: current challenges and next generation blueprint.

Authors:  Y Rajesh; Ipsita Pal; Payel Banik; Sandipan Chakraborty; Sachin A Borkar; Goutam Dey; Ahona Mukherjee; Mahitosh Mandal
Journal:  Acta Pharmacol Sin       Date:  2017-03-20       Impact factor: 6.150

3.  In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation.

Authors:  E Ranza; G Mazzini; A Facoetti; R Nano
Journal:  J Neurooncol       Date:  2009-07-24       Impact factor: 4.130

4.  Tumor progression and oncogene addiction in a PDGF-B-induced model of gliomagenesis.

Authors:  Filippo Calzolari; Irene Appolloni; Evelina Tutucci; Sara Caviglia; Marta Terrile; Giorgio Corte; Paolo Malatesta
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

5.  Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines.

Authors:  F J Swartling; M Ferletta; M Kastemar; W A Weiss; B Westermark
Journal:  Oncogene       Date:  2009-06-22       Impact factor: 9.867

Review 6.  What underlies the diversity of brain tumors?

Authors:  Fredrik J Swartling; Sanna-Maria Hede; William A Weiss
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

7.  GTI: a novel algorithm for identifying outlier gene expression profiles from integrated microarray datasets.

Authors:  John Patrick Mpindi; Henri Sara; Saija Haapa-Paananen; Sami Kilpinen; Tommi Pisto; Elmar Bucher; Kalle Ojala; Kristiina Iljin; Paula Vainio; Mari Björkman; Santosh Gupta; Pekka Kohonen; Matthias Nees; Olli Kallioniemi
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

8.  Myc proteins in brain tumor development and maintenance.

Authors:  Fredrik J Swartling
Journal:  Ups J Med Sci       Date:  2012-02-21       Impact factor: 2.384

Review 9.  Platelet-derived growth factor in glioblastoma-driver or biomarker?

Authors:  Bengt Westermark
Journal:  Ups J Med Sci       Date:  2014-10-24       Impact factor: 2.384

10.  Novel management of glioma by molecular therapies, a review article.

Authors:  Amin Alinezhad; Fatemeh Jafari
Journal:  Eur J Transl Myol       Date:  2019-08-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.